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ABSTRACT 
 
Background: 
This study was performed to evaluate the circulatory and salivary 
levels of Interleukin-17 (IL-17) in periodontal health and disease and to 
correlate it to serum high sensitivity- C reactive protein (hs-CRP) levels. 
Materials & Methods: 
Peripheral blood and saliva samples were collected from forty 
periodontal healthy and diseased patients who were recruited for the study in 
Ragas Dental College and Hospital. Serum was separated from patient’s blood 
and whole unstimulated saliva was centrifuged and subjected to sandwich 
ELISA analysis for quantification of serum and salivary IL-17 levels. Serum 
hs-CRP level was detected by the immunoturbidimetric method. Statistical 
analysis to evaluate the serum and salivary levels of IL-17 was done using the 
independent sample student ‘t’ test and Pearson’s correlation analysis to 
correlate the serum and salivary IL-17 levels to the hs-CRP. 
Results: 
The serum IL-17 level in the periodontally diseased group was 
decreased when compared to the healthy group (D = 23.77 ± 0.43; H = 25.66 ± 
1.06), which was not statistically significant (P = 0.67; P > 0.05). However, 
there was a statistically significant (P = 0.038; P < 0.05) decrease in the 
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salivary IL-17 levels in periodontally diseased group when compared to the 
healthy group (D = 22.24 ± 0.29; H = 24.63 ± 0.93). There was a statistically 
significant increase (P = 0.02; P < 0.05) in hs-CRP levels in periodontal 
disease when compared to health (D = 2.25 ± 0.29; H = 1.16 ± 0.03). There 
was a statistically significant correlation (P = 0.02; P < 0.05) between the 
serum and salivary levels of IL-17 in periodontal disease (serum = 22.24 ± 
0.29; saliva = 23.77 ± 0.43), but there was no statistically significant 
correlation between the serum and salivary levels of IL-17 to that of hs-CRP, 
in the periodontal disease group (IL-17 and circulating hs-CRP levels, P = 
0.706 and/or salivary IL-17 and circulating hs -CRP levels, P = 0.54). 
Conclusion: 
 Salivary IL-17 was significantly decreased in periodontal disease when 
compared to serum IL-17 levels did not correlate with hs-CRP levels. 
Key words:  Th17, IL-17, Periodontitis, periodontal pathogenesis, ELISA. 
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INTRODUCTION 
Periodontal disease is a chronic inflammatory disease, normally the 
result of a specific bacterial infection associated with a complex biofilm 
adhering to the tooth surface, leading to progressive loss of attachment and 
bone4. The tissue destruction in periodontal lesions results from the 
recruitment of the host cells via activation of monocytes/macrophages, 
lymphocytes, and other cell types. T lymphocytes have been postulated to play 
a central role in this process104. The Th1/Th2 paradigm has often been used to 
explain periodontal disease progression but there are still a number of 
unresolved questions regarding this model26. The factors that govern the 
activation and the effector function of the predominant T cell subsets in the 
chronic inflammatory periodontal tissues are not yet fully elucidated85.  
Recently, a T helper subset, termed the Th17 cells, was identified and 
has been proposed to explain some of the short comings of the Th1/Th2 
model. Th17 cells have been suggested to play an important role in 
autoimmune and inflammatory disorders9, 47. Atkins CJ and Bettelli E et al 5, 9, 
showed that the Th17 cells arose in the presence of TGF-β, IL-6, IL-1β and 
were expanded specifically by IL-23. Although the primary effector cytokine 
of these Th17 cells is IL-17, other cytokines such as IL-12, IL-16 and TNF-α, 
are also produced.  
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IL-17 has emerged as a crucial regulator of inflammatory responses17. 
It is known to activate fibroblasts, epithelial cells, endothelial cells and 
osteoblasts to produce pro inflammatory cytokines such as IL-6, IL-8, GCSF 
and MMP102. It is this ability to mediate inflammatory/immune responses that 
has implicated IL-17 in the etiopathogenesis of periodontal disease38.  
Elevated levels of IL-17 have been identified in GCF following 
periodontal disease18. Similarly, increased IL-17 level has been reported in the 
synovial fluid in patients with rheumatoid arthritis and osteoarthritis13. Over 
expression of circulatory IL-17 levels have also been consistently reported in 
inflammatory / autoimmune conditions such as RA and SLE98, 17. Although 
several investigators have demonstrated increased levels of proinflammatory 
cytokines such as IL-1, IL-6, TNF-α (Yamasaki et al 2004) 101, it is not yet 
fully understood if periodontal disease may affect circulating IL-17 levels.  
Whole saliva is an important physiologic fluid that provides a non- 
invasive tool for rapid screening and disease prediction40. Renewed interest in 
salivary diagnostics has resulted from development of point of care, 
microfluidic systems that provide instantaneous data about recent disease 
activity61. Various inflammatory mediators in saliva such as IL-1, IL-6, TNF-
α, IFN-γ, etc, have been identified to correlate with periodontal disease 
activity. Some of the limitations with salivary diagnostics in periodontal 
disease are its lack of its site specificity, variations due to circadian 
rhythmicity and unavailability of one specific disease marker46. Saliva has also 
 Introduction  
 
3 
 
been used to evaluate both local and systemic inflammatory status as it 
contains unique biomarkers that reflect both84. 
In recent years, its ability to reflect systemic disease has been 
extensively investigated. It is not yet fully known which salivary cytokine or 
groups of cytokines produce the most accurate predictive information 
regarding the systemic inflammatory state produced as a result of periodontal 
disease.  
There is scant literature regarding salivary IL-17 activity in periodontal 
disease and its relation, if any, to the systemic inflammatory state. 
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ABSTRACT 
 
Background: 
This study was performed to evaluate the circulatory and salivary 
levels of Interleukin-17 (IL-17) in periodontal health and disease and to 
correlate it to serum high sensitivity- C reactive protein (hs-CRP) levels. 
Materials & Methods: 
Peripheral blood and saliva samples were collected from forty 
periodontal healthy and diseased patients who were recruited for the study in 
Ragas Dental College and Hospital. Serum was separated from patient’s blood 
and whole unstimulated saliva was centrifuged and subjected to sandwich 
ELISA analysis for quantification of serum and salivary IL-17 levels. Serum 
hs-CRP level was detected by the immunoturbidimetric method. Statistical 
analysis to evaluate the serum and salivary levels of IL-17 was done using the 
independent sample student ‘t’ test and Pearson’s correlation analysis to 
correlate the serum and salivary IL-17 levels to the hs-CRP. 
Results: 
The serum IL-17 level in the periodontally diseased group was 
decreased when compared to the healthy group (D = 23.77 ± 0.43; H = 25.66 ± 
1.06), which was not statistically significant (P = 0.67; P > 0.05). However, 
there was a statistically significant (P = 0.038; P < 0.05) decrease in the 
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salivary IL-17 levels in periodontally diseased group when compared to the 
healthy group (D = 22.24 ± 0.29; H = 24.63 ± 0.93). There was a statistically 
significant increase (P = 0.02; P < 0.05) in hs-CRP levels in periodontal 
disease when compared to health (D = 2.25 ± 0.29; H = 1.16 ± 0.03). There 
was a statistically significant correlation (P = 0.02; P < 0.05) between the 
serum and salivary levels of IL-17 in periodontal disease (serum = 22.24 ± 
0.29; saliva = 23.77 ± 0.43), but there was no statistically significant 
correlation between the serum and salivary levels of IL-17 to that of hs-CRP, 
in the periodontal disease group (IL-17 and circulating hs-CRP levels, P = 
0.706 and/or salivary IL-17 and circulating hs -CRP levels, P = 0.54). 
Conclusion: 
 Salivary IL-17 was significantly decreased in periodontal disease when 
compared to serum IL-17 levels did not correlate with hs-CRP levels. 
Key words:  Th17, IL-17, Periodontitis, periodontal pathogenesis, ELISA. 
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REVIEW OF LITERATURE 
Periodontal disease is a chronic inflammatory disease, normally the 
result of a specific bacterial infection associated with complex biofilm 
adhering to the tooth surface, leading to progressive loss of attachment and 
bone4. The tissue destruction in periodontal lesions results from the 
recruitment of the host cells via activation of monocytes / macrophages, 
lymphocytes, fibroblast and other cell types104. 
Ivanyi and lehner et al (1970) 36, demonstrated that the central role 
played by T cells in the pathogenesis of periodontal disease. They are now 
believed to be involved in the homeostasis of periodontal tissue, modulation of 
the inflammatory/immune responses and the mediation of the bone loss 
observed in periodontal disease. 
Classification of T cells:  
T cells are classified based on their function into various categories 
such as helper T (Th) cells, cytotoxic T (Tc) cells and regulatory T (Treg) 
cells. 
T Helper cell subsets: 
 Brostoff J et al (1999) 11 reported that T helper cells were so 
designated because they played a crucial role in the process of antibody 
production by the B cells. Originally the presence of two different subsets of T 
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helper cells Th1 & Th2 was described by Parish & Liew et al (1972) 72. 
Later, Mossman & Coffman et al (1989) 63, delineated two distinct cytokine 
profiles associated with the Th1 and Th2 cells and subsequently, the Th1/Th2 
paradigm has been used to explain the pathogenic mechanisms involved in 
several inflammatory / immune disorders including periodontal disease98. 
Mossmann and Coffman et al (1989) 63 found that the T cells have 
been greatly facilitated by their division into functional subsets. The basis for 
this division was the identification of distinct cytokine production profiles 
among T cell clones, giving rise to T helper Th1 and Th2 subsets. The 
developmental and functional relationship between these prototypic Th subsets 
was subject to intense study and provided the framework for classifying T cell 
responses for almost two decades. These ‘classical’ subsets exemplify the 
characteristics required to claim subset status. They can be differentiated from 
naive T cells under the influence of exogenous cytokines and each express 
unique transcription factors which confer subset-specific expression profiles of 
cytokine production and effector function.  
Sakaguchi F et al (1985) 83, identified a minor subpopulation of CD4+ 
cells capable of preventing the development of autoimmunity which 
revolutionized the concept of T cell regulation. Identification of forkhead box 
P3 (FoxP3) as the lineage-specific transcriptional regulator determining this 
suppressive phenotype confirmed the status of FoxP3+ regulatory T cells 
(Tregs) as distinct from previously described effector subsets37.  
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A newer subset of CD4+ cells termed, the Th17 were then identified28. 
The existence of IL-17 was known previously but it was only with the 
discovery of the distinct subset of Th17 cells that it was recognized as the 
primary source of this cytokine. The Th17 responses are protective against 
certain extracellular bacterial and fungal infections. Dysregulated Th2 
responses promote the development of allergy and asthma, while uncontrolled 
Th1 and Th17 responses can result in autoimmune inflammation; therefore, 
the actions of these effector CD4+ cells need to be controlled strictly. 
Th1/Th2 paradigm/controversies/limitations: 
  Mosmann and Sad (1996) 64 reported that most cloned lines of murine 
CD4+ T cells can be classified into two groups, Th1 and Th2, based on their 
cytokine profiles and their related functional activities. The differentiation of 
CD4+ T cells into Th1 or Th2 is the crucial event in determining whether 
humoral or cell-mediated immunity will predominate. As CD4+ T cells 
differentiate, they are thought to go through an intermediate stage, known as 
ThO. ThO cells express some differentiated effector functions that are 
characteristic of both the inflammatory and the helper T cells. Several lines of 
evidence have demonstrated that IL-4 stimulates differentiation into Th2 cells, 
where as IFN-γ, IL-12, and TGF-β enhance Th1 development64. Mouse Th1 
cells produce interleukin 2 (IL-2), interferon-γ (IFN-γ), and lymphotoxin (LT), 
whereas Th2 cells produce IL-4, IL-5, IL-6, IL-9, IL-10, and IL-13. Human 
Th1 and Th2 cells produce similar patterns, although the synthesis of IL-2, IL-
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6, IL-10, and IL-13 is not as tightly restricted to a single subset as in mouse T 
cells. Several other proteins are secreted by both Th1 and Th2 cells, including 
IL-3, TNF-α, granulocyte-macrophage colony stimulating factor (GM-CSF), 
and members of the chemokine (CK) families. 
The characteristic cytokine products of Th1 and Th2 cells are mutually 
inhibitory for the differentiation and effector functions of the reciprocal 
phenotype. In several cases, alteration of these patterns by cytokine or anti-
cytokine reagents reverses host resistance or susceptibility to infection. 
Mosmann and Sad (1996) 64 showed that there is ample evidence that these 
cytokine patterns are important in mediating resistance to several infectious 
agents. Liblau et al (1995) 48 suggested that Th1 cells contribute to the 
pathogenesis of organ-specific autoimmune diseases, while Th2 cells prevent 
them and protect the host from intracellular and extracellular pathogens and/or 
toxins, respectively.  
Seymour & co-workers (1979) 85 have suggested that the early stable 
periodontal lesion was associated with a robust infiltration of Th1 cells. On the 
contrary Ebersole et al (1994)19 have proposed that a Th2 cytokine profile 
was associated with a stable lesion, while Th1 profile was associated with a 
progressive lesion. 
 The Th1/Th2 paradigm elegantly explained much of the T cell 
mediated immunity: indeed for 20 years, nearly all diseases were pigeonholed 
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into one or the other category in many cases regardless of how poorly they 
actually fit into these models26. However it has long been considered that there 
are nagging discrepancies with respect to the model. In the last few years, the 
discovery of a new CD4+ subset has resolved many of these controversies and 
has simultaneously raised a host of new questions and research directions 97. 
 The role of Th17 cells and their signature cytokine in periodontal 
disease is only beginning to be addressed.       
Development of Th17 cell:  
Chen Y et al (2006) 15 suggested that T cell biology has been enriched 
and enlivened by the description of two further subsets. IL-17 producing T 
cells were identified as important drivers of autoimmune pathology, forcing 
the re-evaluation of the role of Th1 cells in models of autoimmunity. 
Atkins CJ et al (2006) 5 elucidated the factors that promote the 
development of the Th17 cells [transforming growth factor (TGF)-β, IL-6 and 
IL-21] and the regulators of their transcriptional profile (RORγt and RORα) 
established Th17 cells as a third effector T cell subset. The three effector 
subsets appear to have evolved to cope with the threat posed by distinct 
classes of pathogen.  
Infante Duarte et al (2000)33 demonstrated that lipopeptides from 
Borrelia burgdorferi triggered T cell to produce IL-17, TNF-α and GM-CSF, 
cytokines not associated with either the Th1/Th2 lineage. These findings were 
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consistent with reports that IL-17 is not made by Th1/Th2 cells, despite being 
CD4+ cell derived. Agarwal et al 2002 2 demonstrated that IL-23 stimulates 
murine CD4+ T cells to secrete IL-17 following stimulation of the TCR. 
Harrington et al (2005) 28, suggested that the lineage separation 
between Th1 and Th2 cells was solidified with findings that IL-17 secreting 
CD4+ T cells arise in the absence of Th1 and Th2 induced transcription 
factors and cytokines. Thus began an explosion of interest in the generation 
and function of Th17 cells. They are thought to develop in the presence of 
TGF-β, however in synergy with IL-6 / IL-1. In addition, IL-21 and IL-23 
signals are necessary for expansion and stabilization of their phenotype29. Of 
these conductive signals, IL-23 (a member of IL-12 family) has been 
identified in the inflamed tissues as part of the early chemokine / cytokine 
infiltrate66. The presence of IL-6, IL-1 and TGF-β in the chronically inflamed 
gingival tissues is well documented and would seem to create an environment 
conductive to Th17 development79. 
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Ivanov II et al (2006) 35 demonstrated that for Th17 cells, the master 
transcription factor retinoic acid-related orphan receptor gamma (RORγ), is 
required for IL-17 production. RORγ belongs to the super family of steroid 
nuclear receptors and is most closely related to a retinoic acid receptor (RAR) 
subfamily of transcription factors. 
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 Studies have demonstrated that RORγt regulation of IL-17 production 
is not known, nor has it been defined whether RORγt directly or indirectly 
regulates IL-17a gene transcription. One possibility is that RORγt directly 
binds to IL-17a promoter. While a potential ROR binding site is present, it has 
not been demonstrated to be functional. One important means of regulating 
RORγt expression is through cytokines, especially IL-6 and related cytokines. 
IL-6 regulation of RORγt is mediated by STAT3, but it has not been 
established that STAT3 binds the Rorc gene. 
IL-17:  
 Chabaud M et al (1999) 13 stated that IL-17 is a pro inflammatory 
cytokine derived from T cells and produced mainly by cells of Tho/Th1 
phenotype but not cells of Th2 phenotype. 
Abbas et al AK (1996)1 during the past years identified a distinct 
subset of CD4+ T cells that secrete IL-17 and the closely related cytokine IL-
17F as well as other inflammatory cytokines such as IL-6 and IL-22. Currently 
the IL-17 cytokines include a family of six members (IL-17 A-F), with at least 
two of them having potent pro-inflammatory properties, IL-17A or CTLA-8 
and IL-17F. Both are produced by the recently described Th17 cell subset, are 
localized at the same chromosomal locus (1A4), share a 55% of homology at 
the protein level, and seem to have similar function. IL-17A and IL-17F work 
mostly as homodimers, but IL-17A/F heterodimers have been recently 
 
 
 
Review of Literature 
 
13 
 
described in several independent reports (Harrington LE et al 2007)29 
suggesting a role in inflammatory response for regulation of such IL-17 
complexes. 
Kolls J.K and Rose et al (2004)42 found that since IL-17, also called 
IL-17A, was identified a decade ago from activated T cells, other cytokines, 
including IL-17B, C, D, E (also called IL-25) and F have been reported and 
constitute the IL-17 cytokine family. IL-17, the best-studied member in this 
family, is a pro-inflammatory cytokine that was historically associated with 
many inflammatory diseases, such as rheumatoid arthritis, asthma, lupus, and 
allograft rejection.  
Park H et al (2005)73 in his invitro study has shown that the mRNA 
expression of genes encoding several chemokines (CCL2, CCL7, CXCL1, and 
CCL20) and matrix metalloproteinases 3 (MMP3) MMP13 were significantly 
upregulated after IL-17 treatment. Moreover, IL-17 and TNF-α exhibited 
strong synergy in promoting inflammatory gene expression. In vivo, 
overexpression of IL-17 in the lungs resulted in chemokine upregulation and 
tissue infiltration by leukocytes. IL-17 binds to and signals through IL-17RA, 
a member of the IL-17R family102. Though IL-17 is mainly secreted by 
activated T cells, the IL-17 receptor is ubiquitously present in all cells. 
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Effect of IL-17 on individual cell types: 
Chabaud et al (2000)14, reported that T cells are involved in bone 
destruction via IL-17 production in rheumatoid arthritis. IL-17 has been shown 
to stimulate epithelial, endothelial, fibroblastic cells to produce IL-6, IL-8 and 
PGE2. In addition, IL-17 induces RANKL production by osteoblasts44. As IL-
17 shares properties with IL-1 and TNF-α, it may affect osteoclast mediated 
bone resorption. It was also hypothesized that T cells in periodontal lesion 
produce IL-17 and exacerbate inflammatory periodontal disease by activating 
gingival fibroblasts to produce inflammatory mediators. It has also been 
reported that T cells can be directly involved in bone metabolism via T cell 
derived cytokines, receptor activator of NF-κB ligand (RANKL), and 
RANK92.  
Gingival fibroblasts: 
In chronic periodontal lesions, IL-17 has been detected in gingival 
tissue biopsies and gingival crevicular fluid69, 96. IL-17 treatment of HGFs has 
also been observed to lead to IL-6 production, which may contribute to local 
tissue inflammation91. Even so, the underlying mechanisms through which IL-
17 influences development and severity of periodontal disease remain unclear. 
It has been hypothesized that IL-17, especially when combined with IFN-γ, 
may modulate the responses of HGFs 94. 
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Yongvanichit et al 2008103 tested the hypothesis that IL-17, especially 
when combined with IFN-γ, may modulate the responses of human gingival 
fibroblasts (HGFs). IL-17 induced IL-8 and minimal intercellular adhesion 
molecule ICAM-1 expression. It had no effect on expression of HLA-DR, 
CD40, or the immune-suppressive enzyme indoleamine 2,3-dioxygenase 
(IDO). The effects of IL-17 on HGFs were compared with those of IFN-γ. 
Unlike IL-17, IFN-γ augmented the expression of HLA-DR, ICAM-1, and 
IDO, but not IL-8. Thus, IL-17 and IFN-γ induce different HGF responses 
when administered separately. Interestingly, when IL-17 and IFN-γ were 
combined, marked enhancement of ICAM-1, IL-8, and IDO expression by 
HGFs was observed. 
Sorsa et al 200789 hypothesized that the IL-17 has been reported to up-
regulate IL-1β and TNF-α and tissue-destructive matrix metalloproteinases 
(MMP) in local migrant and resident cells. Immunocytochemistry disclosed 
elevated IL-1β, TNF-α, and IL-17 levels in periodontitis. These cytokines 
induced proMMP-1 and especially MMP-3 in gingival fibroblasts, whereas 
MMP-8 and MMP-9 were not induced. IL-17 was less potent as a direct MMP 
inducer than IL-1β and TNF-α, but it induced IL-1β and TNF-α production 
from macrophages, and IL-6 and IL-8 from gingival fibroblasts. In accordance 
with these findings, immunocytochemistry disclosed that MMP-1 and MMP-3 
were increased in periodontitis. Gingival fibroblasts may play an important 
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role in tissue destruction in periodontitis via cytokine-inducible MMP-1 and 
MMP-3 production, in which IL-17 plays a role as a key regulatory cytokine. 
Epithelial cells:  
1. Studies by Linden A et al (2001) 49 demonstrated that Interleukin IL-
17 may contribute to neutrophilic airway inflammation by inducing the 
release of neutrophil-mobilizing cytokines from airway cells. The 
study reported that mitogen activated protein kinases were involved in 
IL-17 induced release of IL-8 and IL-6 in bronchial epithelial cells.  
2. Kawaguchi et al (2001) 41 in a study investigated the role of IL-17, in 
the modulation of primary bronchial epithelial cells, the expression of 
IL-6, IL-8, and intercellular adhesion molecule 1 (ICAM-1) and the 
potential involvement of mitogen-activated protein (MAP) kinases in 
IL-17 mediated signaling. The result showed that IL-17 induced time-
dependent expression of IL-6 and IL-8.  
Osteoblasts: 
 Fang Shen et al (2005)21 demonstrated the spectrum of genes 
controlled by IL-17 and TNF-α in the pre osteoblast cell line MC3T3-E1. The 
genes included pro-inflammatory chemokines and cytokines, inflammatory 
genes, transcriptional regulators, bone remodeling genes, signal transducers, 
cytokine genes and those involved in apoptosis. The CXC family chemokines 
were the most dramatically induced by IL-17, which suggested that IL-17 
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activation of bone cells influenced neutrophil recruitment and subsequent 
amplification of inflammation. 
Role of IL-17 in systemic/autoimmune diseases: 
Rheumatoid arthritis (RA) is a chronic systemic disorder that is 
characterized by autoimmunity, infiltration of joint synovium by activated 
inflammatory cells, synovial hyperplasia, neoangiogenesis and progressive 
destruction of cartilage and bone. RA is considered to be a systemic Th1 
associated inflammatory joint disease, and T cell comprises of the large 
proportion of inflammatory cells invading the synovial tissue. T cell activation 
and migration into the synovium occur as early consequences of the disease, 
and these cells adopt a pro-inflammatory phenotype. Considerable evidence 
now supports a role for T cells in the initiation and perpetuation of chronic 
inflammatory process prevalent in RA. Although T cells represent a large 
proportion of the inflammatory cells during inflammation, T cell derived 
cytokines are much abundant. However, because the vast majority of these are 
memory T cells, IL-17 is up regulated in early disease.    
Johnson et al (2004) 38 found, that IL-17 was significantly elevated in 
the synovial fluid of patients with RA, and was present in osteoarthritic joints 
as well. Bone erosion mediated by over expression of IL-17 has been shown to 
occur through alterations in the RANKL/OPG ratio52.  Furthermore, IL-17 
knockout mice are highly resistant to collagen induced arthritis (Nambu A et 
 
 
 
Review of Literature 
 
18 
 
al 2003) 67 and blocking IL-17 reduces inflammatory symptoms and bone loss 
with CIA95. Conversely, excess IL-17, as provided by adeno-virus-mediated 
gene vectors, exacerbates disease51. 
Katz Y et al (2000) 39 showed that apart from the role of IL-17 in 
autoimmune arthritis, IL-17 and its family member exhibit a potential role in 
other inflammatory diseases, such as lung, gut, and skin inflammation. IL-17 
regulated the gene expression and protein synthesis of a complement system. 
It has a regulatory role on C3 expression and synthesis and an amplifying 
effect on TNF induced factor B synthesis. In addition, IL-17 stimulates 
granulopoesis and was a strong inducer of neutrophil recruitment through 
chemokine release60.  
Antonysamy MA in (1999)3 demonstrated that IL-17 promoted 
angiogenesis and a role for IL-17 was suggested in allogenic T cell 
proliferation that might be mediated in part through a maturation inducing 
effect on dentritic cells. Studies revealed that T cell cytokine had an important 
function in the activation of T cells in allergen specific T cell mediated 
immune responses. IL-17 induced neutrophil accumulation in infected lungs. 
Greatly diminished recruitment of neutrophils into lungs was found in mice 
with homozygous deletion of the IL-17 receptor in response to a challenge 
with a gram negative pathogen. IL-17E transgenic mice showed growth 
retardation, jaundice, a Th2-biased response and a multi organ inflammation75. 
Furthermore, IL-17 expression was observed in ovarian, endometrial and 
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cervical cancers exhibiting an angiogenic effect23. However, further studies 
are needed to unravel the role of IL-17 in the pathogenesis of these 
autoimmune inflammations.           
The role of IL-17 in the bone microenvironment was that it stimulated 
the proliferation of human mesenchymal stem cells (hMSCs). MSCs are 
pluripotent progenitor cells that contribute to the regeneration of mesenchymal 
tissue, including bone, adipose tissue, cartilage, muscle, ligament, tendon, and 
stroma76. IL-17 was shown to increase the formation of fibroblast like colonies 
from bone marrow cells32. The IL-17 dependent signalling pathway that leads 
to increased proliferation of hMSC and showed that generation of reactive 
oxygen species (ROS) is crucial for increased proliferation. Furthermore, the 
results showed that IL-17 also stimulated the migration, motility, and 
osteoblastic differentiation of hMSCs. In addition, IL-17 induces the 
expression of M-CSF and RANKL on hMSCs, thereby stimulating 
osteoclastogenesis. 
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease 
which is in part mediated by the migration of monocytes from blood to RA 
synovial tissue, where they differentiate into macrophages and secrete 
inflammatory cytokines and chemokines. 
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Shahrara S et al (2009)88 in his study has shown that in vivo, IL-17 
mediates monocyte migration into sponges implanted into SCID mice. In 
vitro, IL-17 was chemotactic, not chemokinetic, for monocytes at the 
concentrations detected in the RA synovial fluid. Further, IL-17-induced 
monocyte migration was mediated by ligation to IL-17RA and RC expressed 
on monocytes and was mediated through p38MAPK signaling. Finally, 
neutralization of IL-17 in RA synovial fluid or its receptors on monocytes 
significantly reduced monocyte migration mediated by RA synovial fluid. 
These observations suggest that IL-17 may be important in recruiting 
monocytes into the joints of patients with RA, supporting IL-17 as a 
therapeutic target in RA. 
IL-17 in periodontal disease: 
 The immune cell activation has been long considered to occur 
dominantly as a Th1 or Th2 response. Rose NR et al (2003) 81 found that 
however, numerous diseases cannot be characterized unambiguously as Th1 or 
Th2. An important addition to the Th development model came with the re-
emerging recognition of the T suppressor or Treg cell subset. Treg cells as 
CD4+ CD25+ cells that antagonize Th1 and Th2 immune response, in part by 
secreting suppressive cytokines. Treg cells arise in the presence of 
immunosuppressive cytokine TGF-β and secrete IL-10 and TGF-β80. The Treg 
population mediates resolution of inflammation and can prevent autoimmunity 
in number of animal models. Mottet C et al (2003) 65 showed that Treg cells 
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are believed to play a significant role in preventing chronic, unresolved 
inflammation that is characterized of autoimmune diseases, such as RA, MS 
and colitis.  
 Seymour GJ (1993) 86 discussed the role of Th1 / Th2 subsets in the 
progression of periodontal disease. It was proposed that Th1 response is 
characteristic of a stable lesion, whereas a Th2 response is typical of 
progressive lesion. Alternatively, Th1 cells mediate tissue destruction, 
whereas Th2 cells play a protective role. Dutzan N et al (2005) 18, 
demonstrated that there is little consensus regarding the predominant Th 
subset in periodontal disease, the presence of inflammatory cytokines is well 
established and these cytokines fall into Th1 and Th17 categories. 
Specifically, TNF-α, IFN-γ and IL-1β, IL-2, IL-6, IL-11 and IL-17 were 
identified reproducibly in periodontal pockets and GCF. 
Gingival inflammation begins when endotoxin or bacterial LPS induce 
synthesis of proinflammatory cytokines by gingival cells. Initially cell 
mediated immune response occurs in response to those bacteria. Ellis SD et al 
(1998)20 which results in release of Th1 type cytokine into the gingiva, 
modulating the features and potential spread of the inflammation. The 
inflammation resolves coincident to antibody synthesis by Th2 cell type. 
There is evidence suggesting a defective transition from a Th1 to Th2 cytokine 
profile in the gingiva within periodontitis. There is also evidence for the 
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altered balance between concentrations of pro-inflammatory and anti-
inflammatory cytokines within the microenvironment at several non oral sites.  
 Mitnick MA (2001)62 demonstrated that IL-17 significantly 
upregulated IL-6 expression and in turn IL-6 negatively regulated IL-11 by 
gingival cells suggesting that IL-11 and IL-17 might have significantly 
different function in the pathogenesis of periodontitis. IL-17 is produced by 
activated CD4+ T cells. IL-17 has been suggested to be a fine tuning cytokine 
since it activates both fibroblast and endothelial cells to increase the secretion 
of IL-6 in the presence of TNF-α. The cells of the Th1/Th0 phenotype produce 
IL-17, but not cells of the Th2 phenotype. IL-11 has been reported to have 
anti-inflammatory properties due to its inhibition of the expression of 
proinflammatory cytokine and nitric oxide by macrophages13.  
Studies on GCF levels of IL-17: 
Dutzan N et al (2005)18 determined the presence of IL-17 in gingival 
crevicular fluid (GCF) samples and in the culture supernatants of gingival 
cells from patients with chronic periodontitis. The results showed that the total 
amount of cytokine IL-17 was significantly higher in the periodontitis group 
than the control group. Significantly higher GCF volume and amount of total 
proteins were obtained from periodontitis patients as compared with control 
subjects. A higher concentration of IL-17 was detected in culture supernatants 
from periodontitis patients compared with healthy subjects, either with or 
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without phytohaemagglutinin (PHA) stimulation. Treatment with PHA 
induced a significant increase in the production of IL-17 in healthy subjects 
and periodontitis patients. Therefore the total amount of cytokine IL-17 in 
GCF samples and in the culture supernatants of gingival cells were 
significantly increased in periodontal disease. 
Takashi (2002)93 demonstrated that the role of interleukin-17 (IL-17) 
in the progression of periodontitis focusing on the presence of mRNA 
expression of IL-17 evaluated using RT-PCR and direct sequencing, IL-17 
production in gingival crevicular fluid (GCF) by ELISA and cultured 
periodontitis tissues by Western blot analysis; and whether recombinant 
human IL-17 (rhIL-17) and culture supernatants of periodontitis tissues 
induced IL-6 production from cultured human gingival fibroblasts (HGF). The 
IL-17 mRNA expression in periodontitis tissues were detected, whereas IL-17 
in GCF sample was not detectable. 
In a study by Avani R Pradeep et al (2009)6 the role of IL-17 and IL-
18 in periodontal health and disease and the effect of periodontal treatment on 
its concentration were collected from both the groups. ELISA analysis was 
done to estimate the levels of IL-17 and IL-18. IL-18 levels in GCF increased 
proportionately with the severity of periodontal disease and decreased after 
treatment. IL-17 level in GCF was nearly undetectable. The study concluded 
that absence of IL-17 in GCF indicated that it cannot be considered as a 
biomarker of periodontal disease progression. 
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Buduneli et al (2009)12 in a study evaluated the effects of initial 
periodontal treatment on GCF levels of IL-17, RANKL and OPG in smoking 
and non-smoking patients with chronic periodontitis. The study showed that 
smoking does not affect the GCF levels of IL-17, RANKL and OPG in 
patients with chronic periodontitis. Both smokers and non-smokers were 
affected similarly by the initial periodontal treatment with regard to GCF 
concentration of IL-17 and OPG. 
Berker E et al (2009)8 in a study determined the total amount, 
concentration and ratio of interleukin IL-11 and IL-17 in gingival crevicular 
fluid (GCF) of chronic periodontitis (CP) patients were analyzed by  enzyme-
linked immunosorbent assays. The total amount and concentration of IL-11 
and IL-17 were significantly lower in the Chronic Periodontitis, especially in 
areas with deeper pockets (probing depth ≥ 5mm). The  data confirmed that 
the decreased ratio of IL-11:IL-17 may be a factor, which has shown this 
imbalance between the cytokines activities in deeper pockets. 
Studies on circulatory levels of IL-17:  
Brooks CN et al (2010)10 in view of the inflammatory nature and 
severity of aggressive periodontitis hypothesized that IL-17 might be detected 
in sera from patients with aggressive periodontitis. The results of this study 
showed that IL-17 was barely detectable in sera from periodontally healthy 
individuals, but was present at significantly higher concentrations in sera from 
 
 
 
Review of Literature 
 
25 
 
those with LAgP and GAgP. Multivariate analyses demonstrated associations 
of IL-17 concentrations with periodontal attachment loss, but not with current 
smoking. Therefore, Th17 responses may be characteristic of AgP, and IL-17 
may play a role in the pathogenesis of aggressive periodontitis. 
Luciene Cristina Figueiredo et al (2010)53 evaluated the serum levels 
of tumor necrosis factor-alpha (TNF-α), interferon-γ, and interleukin IL-4, IL-
17 and IL-23 in subjects with generalized chronic periodontitis (GCP) and 
generalized aggressive periodontitis (GAgP) before and after non-surgical 
periodontal therapy. The results demonstrated a significant improvement in 
clinical periodontal status. At baseline, concentrations of TNF-α and IL-17 
were significantly higher in the GAgP group compared to the other groups. 
There was a significant decrease in serum concentrations of TNF-α and IL-17 
at 6 months post-therapy in the GAgP group. The concentration of TNF-α 
remained elevated in the GAgP group compared to the GCP group at 6 months 
post-therapy. 
Salivary diagnostics: 
As a non-invasive technology, saliva diagnostic methods are highly 
attractive. Salivary biomarkers, whether produced by healthy or diseased 
individuals, are sentinel molecules that could be used to scrutinize health and 
perform disease surveillance. 
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 In general, clinical parameters including probing depth, attachment 
level, bleeding on probing (BOP) plaque index (PI) and radiographic loss of 
alveolar bone are used to access disease severity77. Occasionally, monitoring 
of the microbial infection (Listgarten in 1992 and Greenstein in 1988) 50, 27 
and analysis of the host response in gingival crevicular fluid (GCF) are 
utilized in an attempt to identify individuals at risk for future breakdown16, 45. 
Recently, genetic analysis has also been suggested as a means to identify 
individuals who are at high risk for more severe periodontitis43. However, as 
of yet, no clinical or laboratory test is routinely employed in the monitoring of 
patients with periodontal disease. It has long been realized that a rapid and 
simple diagnostic test that can provide a reliable evaluation of periodontal 
disease and identify patients at risk for active disease would be of value to 
both clinicians and patients.  
Saliva is a fluid that can be easily collected, contains locally-derived 
and systemically derived markers of periodontal disease, and hence may offer 
the basis for a patient specific diagnostic test for periodontitis. The fluid 
samples can be considered as whole saliva, and saliva can be collected from a 
specific salivary glands parotid, submandibular and sublingual, as well as 
minor salivary glands54. It can be collected with or without stimulation. 
Whole saliva consists of a mixture of oral fluids, and includes the 
secretion of the major and minor salivary glands, in addition to constituents of 
non salivary origin derived from GCF, expectorated bronchial secretions, 
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serum and blood cells from oral wounds, as well as bacteria and bacterial 
products, viruses and fungi, desquamated epithelial cells and food debris 54. 
Saliva has been used as a diagnostic fluid in medicine55, 22. The use of 
saliva for periodontal diagnosis has been the subject of considerable research 
activity, and proposed marker for disease include proteins of host origin (i.e. 
enzymes, immunoglobulins), phenotypic markers (epithelial keratins), host 
cells, hormones (cortisol), bacteria and bacterial products, volatile compounds 
and ions56.  
 Mansheim.B.J (1980) 57 measured Antibodies against a capsular 
antigen of Bact asaccharolyticus in the serum (IgG) and saliva (IgA) by an 
enzyme-linked immuno-sorbent assay, ELISA. The levels of IgG were present 
in a group of 8 patients with adult, rapidly advancing periodontitis and in 3 
patients with juvenile periodontitis. Antibody levels in periodontitis were not 
significantly different from those of age matched normal subjects. Levels of 
salivary IgA against Bacteria asaccharolyticus determined in healthy 
volunteers and in adult and juvenile periodontitis patients were not statistically 
different among the three groups.  
  Ingman T et al (1993) 34 studied the profile of salivary proteases and 
their cellular origin, with special reference to polymorphonuclear leukocytes 
and bacteria, was studied in localized juvenile periodontitis and compared 
with adult periodontitis and healthy controls. General proteolytic activity in 
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saliva as well as collagenase, elastase-like and trypsin-like activity and 
patients with localized juvenile periodontitis to doxycycline inhibition was 
studied. The saliva of localized juvenile periodontitis patients contained low 
amounts of collagenase compared with adult periodontitis saliva, and almost 
all salivary collagenase was found to exist in endogenously active form, as 
was found to be the case also in adult periodontitis patients and healthy 
controls.  
Over C et al (1993)71 determined the mean levels of myeloperoxidase 
(MPO) in samples of gingival crevicular fluid (GCF), whole saliva and 
peripheral blood neutrophils from patients with rapidly progressive 
periodontitis (RPP) and adult periodontitis (AP) using a spectrophotometric 
method. MPO activity detected in the samples was significantly increased in 
the patient groups when compared to the healthy subjects. The highest MPO 
activity was found in the RPP group. Also the increased MPO activity in 
periodontally diseased patients can be attributed to the increased number of 
neutrophils, the degranulation of these cells and also their hyperactive state in 
the presence of chronic antigenic stimulation. 
  Markkanen H (1986)58 Studied the concentrations of IgA, lysozyme 
and beta 2-microglobulin (beta 2-m) in wax-stimulated mixed saliva from 28 
patients with severe periodontitis and from 28 healthy controls. The 
correlation between IgA and beta 2-m concentrations was highly significant in 
both groups studied (P less than 0.0001, and P less than 0.002), whereas beta 
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2-m and lysozyme concentrations were positively correlated in patients but not 
in controls. A significant correlation between IgA and lysozyme was found 
only in periodontal patients (P less than 0.001). 
 Sandholm L et al (1987) 82 measured the concentration of salivary 
IgG and IgA and the levels of salivary IgG and IgA antibodies to 
Actinobacillus actinomycetemcomitans Y4 by ELISA in 205 persons 
including patients with juvenile and adult periodontitis as well as healthy 
subjects. Compared to the concentration observed in subjects with a healthy 
periodontium, a significantly increased concentration of salivary IgG was 
found in 34% of the patients with moderate adult periodontitis and in 57% of 
the patients with severe adult periodontitis. The level of salivary IgA was less 
influenced by the periodontal condition. The level of salivary IgG antibody to 
A. actinomycetemcomitans was significantly elevated in 55% of the patients 
with untreated juvenile periodontitis and in 28% of the patients treated for JP.  
 Recent advances:  
 As a non-invasive technology, saliva diagnostic methods are highly 
attractive. Salivary biomarkers, whether produced by healthy individuals or by 
individuals affected by specific diseases, are sentinel molecules that could be 
used to scrutinize health and perform disease surveillance. 
Wong DT et al (2006)99 demonstrated that the development of microchips 
and microfluidic platforms for salivary components has great potential in the 
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use of oral fluid for point-of-care testing. Microfluidic and 
microelectromechanical systems are integrated arrangements comprising 
mechanical elements, sensors, actuators and electronics on a common silicon 
substrate developed through microfabrication technology. Researchers are 
designing “lab-on-a-chip” prototypes. These handheld, automated, easy-to-use 
and integrated systems will enable simultaneous and rapid detection of 
multiple salivary protein and nucleic acid targets. 
Barnfather et al (2005)7 investigated the effect of immediate feedback 
from a point-of-care test for salivary nicotine metabolites in promoting 
smoking cessation and reduction in tobacco use. Saliva samples were analyzed 
at presentation and at 8 weeks for salivary nicotine metabolites using a 10 min 
semi-quantitative point-of-care test. They found that a higher smoking 
cessation rate was achieved with the point-of-care test (23% of cases vs. 7% of 
controls; P < 0.039), and overall tobacco use also decreased (68% of cases vs. 
28% of controls; P < 0.001).  
Herr et al (2005)30 reported that microfluidic method facilitates hands-
free saliva analysis by integrating sample pretreatment (filtering, enrichment, 
mixing) with electrophoretic immunoassays to quickly measure analyte 
concentrations in minimally pretreated saliva samples. Rapid (<10 min) 
measurement of levels of the collagen-cleaving enzyme MMP-8 in saliva from 
healthy and periodontally diseased subjects can be achieved using 20 µl of 
saliva. Based on this, a portable diagnostic device called the “Integrated 
 
 
 
Review of Literature 
 
31 
 
Microfluidic Platform for Oral Diagnostics” was developed. An early clinical 
study in which the hand-held Integrated Microfluidic Platform for Oral 
Diagnostics was used to rapidly (3–10 min) measure the concentrations of 
MMP-8 and other biomarkers in small amounts (10 ml) of saliva has been 
reported31.   
Miller et al (2007)61 reported application of a lab-on-a-chip system for the 
concomitant measurement of the salivary biomarkers C-reactive protein, 
MMP-8 and IL-1β as related to the clinical expression of periodontitis and he 
demonstrates that the results achieved by the lab-on-a-chip approach are in 
agreement with those acquired by standard enzyme-linked immunosorbent 
assay, with significant IL-1β and MMP-8 increases in whole saliva of 
periodontitis patients. The results of the lab-on-a-chip assay were linear for 
three orders of magnitude, whereas those of the enzyme-linked 
immunosorbent assay were only linear for two orders of magnitude. The 
availability of more sophisticated analytic techniques gives cause for optimism 
that saliva will eventually be the biomedium of choice in clinical diagnostics. 
These salivary biomarker detectors can be used in the office of a dentist or 
another health care provider for point-of-care disease screening and detection. 
Studies on salivary levels in IL-17: 
Stewart C et al (2008)90 studied that the Th1/Th2 paradigm has been 
expanded by the discovery of Th17 cells, a subset of CD4+ memory T cells 
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characterized by their unique ability to secrete interleukin-17 (IL-17) family 
cytokines. Importantly, Th17 cells appear to be intimately involved in 
autoimmunity. The study was made to investigate whether the Th17/IL-23 
system is up-regulated in (SS). Sera, saliva, and salivary glands from 
C57BL/6.NOD-Aec1Aec2 mice (a model for primary SS), as well as sera, 
saliva, and salivary gland biopsy specimens obtained from patients with 
primary SS, were evaluated for IL-17 and IL-23 expression by 
immunohistochemistry, real-time polymerase chain reaction, and the Luminex 
system. The results suggested that the Th17/IL-23 system is up-regulated in 
C57BL/6.NOD-Aec1Aec2 mice and SS patients at the time of disease. A 
correlation between up-regulated IL-17/IL-23 expression and specific clinical 
manifestations of Sjogren's syndrome has yet to be identified.  
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MATERIALS AND METHODS 
Study Population: 
40 patients who attended the out patient Department of Ragas Dental 
College and Hospitals, Chennai were enrolled in the study. Patients were 
divided into two groups based on their periodontal health status. Informed 
consent was obtained from all the patients. The study was undertaken 
following approval from the institutional review board. 
Selection criteria: 
Group A: Healthy Gingiva - Patients exhibiting no signs of periodontal 
disease, determined by the absence of clinical attachment loss, absence of 
bleeding on probing in < 10% of sites. Probing Pocket Depth of <3mm. 
Group B: Comprises of Chronic Periodontitis Patients with teeth 
exhibiting PPD ≥ 5 mm and CAL ≥ 3mm and radiographic evidence of bone 
loss in atleast 6 teeth, who were otherwise systemically healthy on general 
examination in Ragas General Hospital. 
Chronic periodontitis patients were categorised according the BGI 
index (Offenbacher et al 2007)70. Five levels of disease were defined based 
upon shallow (PD ≤ 3mm) or deep (PD ≥ 4mm) and Probing Depths in 
combination with low or high bleeding scores. The BGI-H was defined as all 
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PDs ≤ 3mm and < 10% BOP; BGI-gingivitis (BGI-G) was defined as 
individuals with all PDs ≤ 3 mm and ≥ 10% BOP. Three BGI deep lesion (DL) 
groups were created based upon full mouth PD and BOP scores. BGI-deep 
lesion/low bleeding (BGI-DL/LB) was defined as one or more sites with PD ≥ 
4 mm and BOP extent scores < 10%; BGI-DL/moderate bleeding (BGI-
DL/MB) was defined as one or more sites with PD ≥ 4 mm and BOP extent 
scores between 10% and 50%; and BGI-DL/severe bleeding (BGI-DL/SB) 
included subjects with one or more sites with PD ≥4 mm and BOP extent 
scores ≥50%. These five BGI categories created a gradient of disease severity 
while creating categories that differed by biologic phenotype at site-based and 
patient-based levels. 
Exclusion criteria: 
• Patients with history of periodontal therapy or antibiotic therapy and 
other medication in the last 6 months  
• Patients with history of systemic diseases that may affect the 
periodontal status 
• Pregnancy and Lactation 
• Smokers 
• Evidence of any other active oral infections eg: pulpal pathology. 
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SAMPLE COLLECTION: 
SERUM SAMPLE: 
3ml of Peripheral blood was drawn from patients using venepuncture 
from the antecubital fossa and transferred using sterile test tubes and used for 
ELISA analysis. 
Peripheral blood was drawn prior to onset of Phase I periodontal 
therapy in periodontitis patients. All patients underwent complete 
hematological investigation to rule out systemic diseases and conditions. 
SALIVA SAMPLE: 
Salivary samples were collected according to the technique described 
by Navazesh Mahvash et al 200868. 
The patients were advised to refrain from intake of any food or 
beverage (water exempted) at least one hour before the test session. Smoking, 
chewing gum and intake of coffee were also prohibited during this hour. The 
subjects were advised to rinse his or her mouth several times with distilled 
water and then to relax for five minutes. 
During collection of saliva the patient were advised to make every 
effort to minimize movement, particularly movements of the mouth. Patients 
were asked to swallow to void the mouth of saliva. Then the patients were 
asked to lean the head forward over the container with the mouth slightly open 
and allow the saliva to drain into the container with the eyes open.  
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ARMAMENTARIUM 
1. Disposable needle and syringe 
 2.  Vaccutainers 
 3.  Test Tubes 
 4.  Centrifuge Tubes 
 5.  Micropipettes 
 6.  Micropipette tips 
 7.  Pasteur pipette 
 8.  Laboratory Centrifuge 
 9.  Refridgerator                                                       
10. Ice pack (for transfer) 
11. Sterile saliva containers 
 
Serum sample preparation:- 
2ml of the 3ml blood that was drawn was allowed to clot at room temperature 
for 30 mins and centrifuged at 3000 rpm for 10 mins. Serum was then 
transferred to a labelled poly propylene tube and stored at -70o c. 
Saliva preparation: 
The collected saliva is centrifuged at 3000 rpm at 4°C for 5min. The 
supernatant fraction is then separated and then stored at −80°C.  
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REAGENT PREPARATION 
All reagents were brought to room temperature before use. 
Wash Buffer: 
 The crystals in the concentrate were warmed to room temperature and 
mixed gently until the crystals have dissolved completely. 20 ml of Wash 
Buffer Concentrate were diluted into deionised or distilled water to prepare 
500 ml of Wash Buffer. 
Substrate Solution: 
 Color Reagents A and B were mixed together in equal volumes within 
15 minutes of use and was protected from light. 200 µL of the resultant 
mixture was required per well. 
IL-17 Standard: 
 IL-17 Standard was reconstituted with 1.0 ml of deionised or distilled water. 
This reconstitution produced a stock solution of 20000 pg/ml. The standard 
was allowed to sit for a minimum of 15 minutes with gentle agitation prior to 
making dilutions. 900 µl of the Calibrator Diluent RD6-21 was pippetted (for 
serum/plasma samples) into the 2000 pg/ml tube. 500 µl of Calibrator Diluent 
was pippetted into the remaining tubes. The stock solution was used to 
produce a dilution series (below). Each tube was thoroughly mixed before the 
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next transfer. The 2000 pg/ml standard served as the high standard. The 
appropriate Calibrator Diluent serves at the zero standards (0 pg/ml). 
ASSAY PROCEDURE: 
 All reagents and samples were brought to room temperature before use.  
1. Excess microplate strips from the plate frame were removed and returned 
to the foil pouch containing the desiccant pack, and resealed. 
2. 100 µl of Assay Diluent RD1-36 was added to each well. 
3. 100 µl of Standard, control, or sample were added per well. Reagent 
addition was uninterrupted and completed within 15 minutes. It was 
covered with the adhesive strip provided and incubated for 3 hours at 
room temperature. 
4. Each well was aspirated and washed, repeating the process twice for a 
total of three washes. Each well was filled with Wash Buffer (400 µl) 
using a squirt bottle. After the last wash, any remaining Wash Buffer 
was removed by aspirating or decanting. The plate was inverted and 
blotted it against clean paper towels. 
5. 200 µL of IL-17 Conjugate was added to each well. It was covered with 
a new adhesive strip and incubated for 1 hour at room temperature.  
6. The aspiration/wash was repeated as in step 4. 
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7. 200 µl of Substrate Solution was added to each well and incubate for 30 
minutes at room temperature. It was protected from light. 
8. 50 µL of Stop Solution was added to each well. The colour in the wells 
changed from blue to yellow. If the colour in the wells turned green or 
the colour change did not appear uniform, the plate was gently tapped to 
ensure thorough mixing. 
9. The optical density of each well was determined within 30 minutes, 
using a microplate reader set to 450 nm. Wavelength correction was 
made by subtracting readings at 540 nm from the readings at 450 nm. 
This subtraction will correct for optical imperfections in the plate. This 
procedure was followed as readings made directly at 450 nm without 
correction may be higher and less accurate. 
Measurement of High Sensitivity C-Reactive Protein (hs-CRP):- 
Measurement of hs-CRP was performed using a immunoturbidimetric 
assay performed on a Randox Daytoner analyzer (Randex Laboratories, 
Crumlin Co., Autrium, UK). The assay range was 0.1 to 20 mg/l and detection 
limit was 0.03 mg/l. 
CALCULATION OF RESULTS 
The duplicate readings for each standard, control, and sample were 
averaged and subtracted from the average zero standard optical density. 
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The optical density of the standard versus the concentration of the 
standards was plotted and the curve was drawn. The data was linearized by 
using log/log paper and regression analysis was applied to the log 
transformation. 
The IL-17 concentration for each samples were determined using the 
standard graph /curve plotted.  
Statistical analysis:- 
 The serum and salivary levels of IL-17 levels in periodontally 
healthy and diseased patients was compared by calculating the mean and 
standard deviation for each group. Student ‘t’ test was used for statistical 
analysis and p value was calculated. Correlation coefficient of serum and 
saliva in periodontal health and disease was analysed using Pearson’s 
correlation. p < 0.05 was considered to be statistically significant at the 5% 
level. 
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MATERIALS AND METHODS
Study Population: 
40 patients who attended the out patient Department of Ragas Dental 
College and Hospitals, Chennai were enrolled in the study. Patients were 
divided into two groups based on their periodontal health status. Informed 
consent was obtained from all the patients. The study was undertaken 
following approval from the institutional review board. 
Selection criteria: 
Group A: Healthy Gingiva - Patients exhibiting no signs of periodontal 
disease, determined by the absence of clinical attachment loss, absence of 
bleeding on probing in < 10% of sites. Probing Pocket Depth of <3mm. 
Group B: Comprises of Chronic Periodontitis Patients with teeth 
exhibiting PPD  5 mm and CAL  3mm and radiographic evidence of bone 
loss in atleast 6 teeth, who were otherwise systemically healthy on general 
examination in Ragas General Hospital.
Chronic periodontitis patients were categorised according the BGI 
index (Offenbacher et al 2007)70. Five levels of disease were defined based 
upon shallow (PD  3mm) or deep (PD  4mm) and Probing Depths in 
combination with low or high bleeding scores. The BGI-H was defined as all 
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PDs  3mm and < 10% BOP; BGI-gingivitis (BGI-G) was defined as 
individuals with all PDs  3 mm and  10% BOP. Three BGI deep lesion (DL) 
groups were created based upon full mouth PD and BOP scores. BGI-deep 
lesion/low bleeding (BGI-DL/LB) was defined as one or more sites with PD 
4 mm and BOP extent scores < 10%; BGI-DL/moderate bleeding (BGI-
DL/MB) was defined as one or more sites with PD  4 mm and BOP extent 
scores between 10% and 50%; and BGI-DL/severe bleeding (BGI-DL/SB) 
included subjects with one or more sites with PD 4 mm and BOP extent 
scores 50%. These five BGI categories created a gradient of disease severity 
while creating categories that differed by biologic phenotype at site-based and 
patient-based levels. 
Exclusion criteria: 
x Patients with history of periodontal therapy or antibiotic therapy and 
other medication in the last 6 months  
x Patients with history of systemic diseases that may affect the 
periodontal status 
x Pregnancy and Lactation 
x Smokers 
x Evidence of any other active oral infections eg: pulpal pathology. 
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SAMPLE COLLECTION: 
SERUM SAMPLE: 
3ml of Peripheral blood was drawn from patients using venepuncture 
from the antecubital fossa and transferred using sterile test tubes and used for 
ELISA analysis.
Peripheral blood was drawn prior to onset of Phase I periodontal 
therapy in periodontitis patients. All patients underwent complete 
hematological investigation to rule out systemic diseases and conditions. 
SALIVA SAMPLE: 
Salivary samples were collected according to the technique described 
by Navazesh Mahvash et al 200868.
The patients were advised to refrain from intake of any food or 
beverage (water exempted) at least one hour before the test session. Smoking, 
chewing gum and intake of coffee were also prohibited during this hour. The 
subjects were advised to rinse his or her mouth several times with distilled 
water and then to relax for five minutes. 
During collection of saliva the patient were advised to make every 
effort to minimize movement, particularly movements of the mouth. Patients 
were asked to swallow to void the mouth of saliva. Then the patients were 
asked to lean the head forward over the container with the mouth slightly open 
and allow the saliva to drain into the container with the eyes open.  
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ARMAMENTARIUM
1. Disposable needle and syringe 
 2.  Vaccutainers 
 3.  Test Tubes 
 4.  Centrifuge Tubes 
 5.  Micropipettes 
 6.  Micropipette tips 
 7.  Pasteur pipette 
 8.  Laboratory Centrifuge 
 9.  Refridgerator                                                       
10. Ice pack (for transfer) 
11. Sterile saliva containers 
Serum sample preparation:- 
2ml of the 3ml blood that was drawn was allowed to clot at room temperature 
for 30 mins and centrifuged at 3000 rpm for 10 mins. Serum was then 
transferred to a labelled poly propylene tube and stored at -70o c. 
Saliva preparation: 
The collected saliva is centrifuged at 3000 rpm at 4°C for 5min. The 
supernatant fraction is then separated and then stored at í80°C.
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REAGENT PREPARATION 
All reagents were brought to room temperature before use.
Wash Buffer:
 The crystals in the concentrate were warmed to room temperature and 
mixed gently until the crystals have dissolved completely. 20 ml of Wash 
Buffer Concentrate were diluted into deionised or distilled water to prepare 
500 ml of Wash Buffer. 
Substrate Solution: 
 Color Reagents A and B were mixed together in equal volumes within 
15 minutes of use and was protected from light. 200 μL of the resultant 
mixture was required per well. 
IL-17 Standard: 
 IL-17 Standard was reconstituted with 1.0 ml of deionised or distilled water. 
This reconstitution produced a stock solution of 20000 pg/ml. The standard 
was allowed to sit for a minimum of 15 minutes with gentle agitation prior to 
making dilutions. 900 μl of the Calibrator Diluent RD6-21 was pippetted (for 
serum/plasma samples) into the 2000 pg/ml tube. 500 μl of Calibrator Diluent 
was pippetted into the remaining tubes. The stock solution was used to 
produce a dilution series (below). Each tube was thoroughly mixed before the 
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next transfer. The 2000 pg/ml standard served as the high standard. The 
appropriate Calibrator Diluent serves at the zero standards (0 pg/ml). 
ASSAY PROCEDURE:
 All reagents and samples were brought to room temperature before use.  
1. Excess microplate strips from the plate frame were removed and returned 
to the foil pouch containing the desiccant pack, and resealed. 
2. 100 μl of Assay Diluent RD1-36 was added to each well. 
3. 100 μl of Standard, control, or sample were added per well. Reagent 
addition was uninterrupted and completed within 15 minutes. It was 
covered with the adhesive strip provided and incubated for 3 hours at 
room temperature. 
4. Each well was aspirated and washed, repeating the process twice for a 
total of three washes. Each well was filled with Wash Buffer (400 μl) 
using a squirt bottle. After the last wash, any remaining Wash Buffer 
was removed by aspirating or decanting. The plate was inverted and 
blotted it against clean paper towels. 
5. 200 μL of IL-17 Conjugate was added to each well. It was covered with 
a new adhesive strip and incubated for 1 hour at room temperature.  
6. The aspiration/wash was repeated as in step 4. 
Materials and Methods 

39

7. 200 μl of Substrate Solution was added to each well and incubate for 30 
minutes at room temperature. It was protected from light. 
8. 50 μL of Stop Solution was added to each well. The colour in the wells 
changed from blue to yellow. If the colour in the wells turned green or 
the colour change did not appear uniform, the plate was gently tapped to 
ensure thorough mixing. 
9. The optical density of each well was determined within 30 minutes, 
using a microplate reader set to 450 nm. Wavelength correction was 
made by subtracting readings at 540 nm from the readings at 450 nm. 
This subtraction will correct for optical imperfections in the plate. This 
procedure was followed as readings made directly at 450 nm without 
correction may be higher and less accurate. 
Measurement of High Sensitivity C-Reactive Protein (hs-CRP):- 
Measurement of hs-CRP was performed using a immunoturbidimetric 
assay performed on a Randox Daytoner analyzer (Randex Laboratories, 
Crumlin Co., Autrium, UK). The assay range was 0.1 to 20 mg/l and detection 
limit was 0.03 mg/l. 
CALCULATION OF RESULTS 
The duplicate readings for each standard, control, and sample were 
averaged and subtracted from the average zero standard optical density. 
Materials and Methods 

40

The optical density of the standard versus the concentration of the 
standards was plotted and the curve was drawn. The data was linearized by 
using log/log paper and regression analysis was applied to the log 
transformation. 
The IL-17 concentration for each samples were determined using the 
standard graph /curve plotted.  
Statistical analysis:- 
 The serum and salivary levels of IL-17 levels in periodontally 
healthy and diseased patients was compared by calculating the mean and 
standard deviation for each group. Student ‘t’ test was used for statistical 
analysis and p value was calculated. Correlation coefficient of serum and 
saliva in periodontal health and disease was analysed using Pearson’s 
correlation. p < 0.05 was considered to be statistically significant at the 5% 
level. 
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DISCUSSION 
Chronic periodontitis is a chronic inflammatory disease that affects 
the attachment apparatus of the teeth. Although periodontopathic bacteria 
are the primary etiological agents in periodontal disease, the ultimate 
determinant of disease progression and clinical outcome is the host's 
immune response87. 
It is generally accepted that the periodontal disease results from an 
imbalance between the Th1/ Th2 cytokines resulting in excessive pro-
inflammatory activity. These pro-inflammatory cytokines exhibit a systemic 
spill over and are in this manner; thought to be capable of mediating the 
course of systemic disease such as Rheumatoid arthritis, CVD, Diabetes 
etc74, 24, 59. The more recently identified Th17 cells and their signature 
cytokine IL-17 has been postulated to be involved in autoimmune and 
inflammatory disorders. It is not yet known if circulatory IL-17 levels are 
affected by periodontal disease.    
Saliva is an important physiologic fluid that has been established as a 
simple and non invasive diagnostic tool that allows rapid screening, 
provides accurate and predictive information and enables reliable evaluation 
of the local and systemic inflammatory status, as it contains unique 
biomarkers that reflects both84. Although several cytokines in saliva such as 
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IL-1β have been used as disease markers; IL-17 has not yet been extensively 
investigated. This study was undertaken to determine the circulatory and 
salivary levels of IL-17 in periodontally healthy and diseased patients and to 
correlate it with the systemic inflammatory marker, hs CRP. 
All patients were categorized into periodontally healthy and disease 
groups according to well established guidelines (Armitage et al 1999) 4. The 
BGI index was used to further categorize the periodontitis group as this has 
been reported to be a sensitive indicator of systemic inflammation 
associated with periodontal disease only those which belonged to the BGI-
DL category was included. In this study, the patients examined on the BGI 
category belonged either to the Moderate Bleeding (MB) and Severe 
Bleeding (SB) group; there were no patients in the Low Bleeding (LB) 
category.  
Blood and salivary samples were obtained from both the groups. 
Serum was obtained from centrifugation of blood sample. Saliva was 
collected according to Navezesh et al 68 method of collection, after which 
serum and salivary IL-17 levels were analyzed using ELISA analysis. hs 
CRP levels in serum was assessed using the immunoturbidity method. 
 Circulatory hs CRP levels were significantly elevated in periodontal 
disease when compared to health, suggesting that periodontal disease does 
indeed lead to systemic inflammation. These results are in accordance with 
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the results of Renvert, Nakajima et al 78. Our results showed that there was 
no statistically significant difference in the circulatory levels of IL-17 
between periodontal health and disease groups. These results are in 
agreement with those obtained by Infant Duarte et al 33. These authors 
reported elevated IL-17 levels only in aggressive periodontitis patients who 
were not included in our study. It has been postulated that the difference in 
etiopathogenic mechanism between chronic periodontitis and aggressive 
periodontitis may be responsible for the differing circulating IL-17 
observed in both the conditions. Although a systemic spill over of 
proinflammatory cytokines is extensively documented; there is no universal 
agreement about the contribution of these cytokines, either individually or 
collectively, to the systemic inflammatory status, (Genco et al 2002) 25. 
Circulatory IL-17 levels did not correlate significantly with hs CRP. 
The result suggests that IL-17 may not be an important contributory factor 
to the systemic inflammatory state caused by periodontal disease. There 
were no previous reports of this nature with which we could compare our 
results. 
Previous studies have reported that the circulatory IL-17 was 
significantly elevated and closely related to disease activity in inflammatory 
bone disorders such as rheumatoid arthritis (RA)13. RA is however an 
autoimmune disorder and therefore the pathogenic mechanisms may 
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involve IL-17 to a greater extent when compared to periodontal disease. 
The circulating IL-17 levels did not show any significant correlation with 
the BGI status, but the small sample size presented a meaningful analysis. 
When the salivary IL-17 levels were examined; there was a 
significant decrease in IL-17 in periodontal disease when compared to 
health. This was some what an contrary result as previous studies have 
mostly reported an increased level of this proinflammatory cytokine in 
exudates such as GCF18, 96. Most salivary markers of periodontal disease are 
thought to be derived from GCF and it may be thus postulated that GCF 
levels could closely correspond to the salivary levels. Previous studies on 
GCF may thus be used as a basis of comparison.  
Our results may not be attributed to experimental error due to the 
following reasons;  
1. The results were consistent in both the health and disease groups, 
with only a small SD around the mean. This may be interpreted to 
mean that the values obtained were not error prone. 
2. All experimental procedures starting from the collection of saliva 
were performed in the same standardized conditions.  
Our results are more in agreement with the results of Berker et al 8, 
who demonstrated decreased IL-17 levels in chronic periodontitis 
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especially when pockets are deeper than ≥ 5mm. It is possible that the 
clinical status of the periodontitis patients in our study matched closely 
with that of Berker et al8, than that included in the Dutzan et al18, 96 
studies. However, Avani Pradeep et al6, reported that IL-17 was 
undetectable in GCF.  As we used saliva in this study; the greater 
volume of fluid obtained could have resulted in above detection limits 
in our study. This could be postulated to be the reason for our ability to 
detect IL-17 in saliva although we used the same methodology. The 
results of our study are thus in agreement with a few previous reports 
but contrary to most others.   
We hypothesize that the reduction in IL-17 could be due to the 
following reasons; 
1) Although considered to be predominantly pro-inflammatory in nature, a 
dichotomous role for IL-17 has been suggested for in both auto immune 
and inflammatory diseases38. 
2) Th17 cells have been postulated to be involved in host defense against 
extra cellular bacteria primarily through influencing neutrophil 
recruitment to the site of infection71. IL-17 may be involved in 
regulating this early inflammatory event and may potentially play other 
roles in the later stages of established periodontal disease. This may be 
the reason for its reduction in the periodontitis group. 
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3) IL-17 is capable of exerting its effect on several cell types of the 
periodontal tissues such as epithelial cells, fibroblast, osteoblast etc14. It 
is therefore plausible that most of the cytokine produced could have 
been used up in the tissue itself to sustain the inflammatory process. 
Therefore even if there had been an upregulation of the 
proinflammatory cytokine; this excessive production may have resulted 
in increased utilization within the periodontal tissues thereby 
perpetuating the inflammatory process. Consequently, there may have 
been a decrease in IL-17 level in tissue exudates and therefore saliva. 
There is however very little previous literature supporting this 
hypothesis. There are few reports on IL-17 mRNA expression or the 
receptor IL-17R expression in gingival tissue or indeed IL-17+ cells in 
tissues in existing literature.  
Regardless of the mechanism involved, it is an interesting finding 
that salivary IL-17 was reduced in periodontal disease when compared 
to health. No single cytokine has been shown to be effective in disease 
prediction. It has been suggested that considering the complex 
etiopathogenic mechanisms involved a cocktail of markers may be 
required to accurately assess the periodontal disease. Our results suggest 
that periodontal disease may not be always associated with upregulation 
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of inflammatory markers; IL-17 and perhaps other cytokines may be 
down regulated in fluids such as saliva. 
Salivary IL-17 could not be correlated with the BGI status, but the 
small sample size of the sub groups could have interfered with the 
statistical analysis. These findings certainly warrant further 
investigation. The salivary IL-17 did not correspond to the systemic 
inflammatory marker hs CRP, indicating that it cannot be used as a 
surrogate marker of inflammation. 
Another interesting finding in this study was that the salivary and 
circulating IL-17 significantly correlated with each other in periodontal 
disease, but not in health. These results suggest that a dysregulation of 
IL-17 had occurred in periodontal disease. However, its exact role in the 
etiopathogenic process is yet to be fully understood.   
The overall analysis of our result suggests that IL-17 is involved 
primarily as a mediator of local rather than systemic inflammation.  
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Limitations of our study include:  
1. A small sample size. 
2. Cross sectional nature of the study, longitudinal studies are 
thought to be more effective in identifying disease markers. 
3. IL-17+ cells or IL-17 mRNA in tissue was not detected. They 
could have perhaps given a more complete exact picture. 
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RESULTS 
Blood and saliva samples were collected from 40 periodontally healthy 
and diseased subjects. Serum was obtained from centrifugation of blood. 
Sandwich ELISA was carried out to evaluate the circulatory and salivary levels of 
IL-17 in periodontal health and disease. High sensitivity CRP (hs-CRP) was 
evaluated by an immunoturbidity assay using an automated analyzer.  
Evaluation of circulatory levels of IL-17: 
The mean serum IL-17 levels in the periodontal health group was 25.66 ± 
1.05 pg/ml, while the mean IL-17 levels in the periodontitis group was 23.77 ± 
0.43 pg/ml. There was no statistically significant difference in the serum IL-17 
levels of the periodontal health and disease groups P = 0.677, (P > 0.05). 
Evaluation of salivary levels of IL-17: 
The mean salivary IL-17 levels in periodontal health group was 24.63 ± 
0.93 pg/ml, while the mean IL-17 levels in periodontitis group was 22.24 ± 0.29 
pg/ml. There was statistically significant decrease in periodontal disease when 
compared to health P = 0.03, (P < 0.05).  
 
 
 
 
Results  
 
 
 
42 
 
Measurement of serum of hs-CRP in periodontal health and disease: 
There was a statistically significant increase in hs-CRP levels in 
periodontal disease groups when compared to the healthy groups, [Health = 1.16 
± 0.033 pg/ml; Disease = 2.25 ± 0.29 pg/ml, P = 0.008, (P < 0.05)]. 
Correlation analysis of the serum and salivary IL-17 levels in periodontal 
disease: 
The Pearsons correlation analysis was used to correlate the serum and 
salivary levels of IL-17 in periodontal disease. There was a statistical significant 
correlation between the circulatory and salivary levels of IL-17 in periodontal 
disease P = 0.0248 (P < 0.05), while there was no significant correlation between 
the circulatory and salivary levels of IL-17 in periodontal health p = 0.8974 (P > 
0.05). 
Correlation analysis of the serum and salivary levels of IL-17 with hs-CRP in 
periodontal disease: 
There was no statistically significant correlation between circulating IL-17 
and hs CRP levels (P = 0.706). Similarly, there was no significant correlation 
between salivary circulating IL-17 and hs CRP levels (P = 0.538). 
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SUMMARY AND CONCLUSION 
 It is generally accepted that periodontal disease results from an 
imbalance of the T helper subset cytokines resulting in excessive pro-
inflammatory activity in active periodontal disease. The role of IL-17 a 
signature cytokine of Th17 subset in periodontal disease and its contribution 
to systemic inflammation has not yet been fully elucidated. So this study was 
undertaken to  
1. Evaluate the circulatory and salivary levels of IL-17 in periodontal 
disease. 
2. Investigate if the circulatory IL-17 levels correspond to the salivary 
IL-17 levels and to hs CRP, a known marker of systemic 
inflammation.   
 The circulatory and salivary IL-17 levels were analyzed by ELISA 
and hs CRP by immunoturbidity method. The results of all study showed 
that there was no statistically significant difference in the circulatory IL-17 
levels between periodontal health and disease p = 0.6779 (p > 0.05), while 
the salivary IL-17 levels was showed a statistically significantly reduction 
in periodontal disease when compared to health p = 0.0385 (p < 0.05). 
Although the circulatory IL-17 levels correlated significantly with salivary 
IL-17 levels p = 0.0248 (p < 0.05), both showed a poor correlation to hs 
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CRP (circulating IL-17; hs CRP p = 0.706) and (salivary IL-17; circulatory 
hs CRP p = 0.538). 
From these result we may conclude that;   
1. There was no significant difference in circulating IL-17 levels in 
periodontal health and disease. 
2. Salivary IL-17 level was significantly decreased in periodontal 
disease when compared to health. 
3. Salivary and circulating IL-17 correlated with each other in 
periodontal disease but not with hs CRP. 
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